- Home
- IMNM
IMNM
Immunome Inc.
as 12-18-2024 12:38pm EST
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BOTHELL |
| Market Cap: | 747.7M | IPO Year: | 2020 |
| Target Price: | $28.60 | AVG Volume (30 days): | 803.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.76 - $30.96 | Next Earning Date: | 11-13-2024 |
| Revenue: | $10,129,000 | Revenue Growth: | -0.62% |
| Revenue Growth (this year): | -31.5% | Revenue Growth (next year): | -60.12% |
Stock Insider Trading Activity of Immunome Inc. (IMNM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SIEGALL CLAY B | IMNM | President and CEO | Nov 21 '24 | Buy | $9.66 | 100,000 | $962,181.46 | 485,693 | |
| Tsai Philip | IMNM | Chief Technology Officer | Nov 21 '24 | Buy | $9.43 | 21,000 | $198,030.00 | 21,000 | |
| Lechleider Robert | IMNM | Chief Medical Officer | Nov 21 '24 | Buy | $9.48 | 15,805 | $149,799.79 | 15,805 | |
| Rosett Max | IMNM | Chief Financial Officer | Sep 19 '24 | Sell | $16.01 | 14,380 | $230,223.80 | 47,476 |
Latest Immunome Inc. News
IMNM Breaking Stock News: Dive into IMNM Ticker-Specific Updates for Smart Investing
Business Wire
16 days ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
21 days ago
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
Argus Research
22 days ago
Daily – Vickers Top Buyers & Sellers for 11/26/2024
MT Newswires
23 days ago
Immunome Insider Bought Shares Worth $962,181, According to a Recent SEC Filing
MT Newswires
a month ago
Immunome Files Prospectus for Stock Offering By Selling Shareholders
Simply Wall St.
a month ago
Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Zacks
a month ago
Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates
Business Wire
a month ago
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
Compare IMNM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMNM Immunome Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.